SCHEMBL2193744

SCHEMBL2193744

Nc1ccc(O)nc1Nc1ccccc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 1/20 0.46
KMT2A Q03164 5/20 0.45
TSHR P16473 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
IGF1R P08069 1/20 0.43
CDK5 Q00535 1/20 0.43
CDK5R1 Q15078 1/20 0.43
TTBK1 Q5TCY1 1/20 0.42
TTBK2 Q6IQ55 1/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
RAD52 P43351 1/20 0.40
KDM4E B2RXH2 2/20 0.40
AURKA O14965 2/20 0.40
EGFR P00533 1/20 0.40
HSD17B10 Q99714 1/20 0.40
ALDH1A1 P00352 2/20 0.39
LCK P06239 1/20 0.39
MAPT P10636 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2192571 0.85 MAPT (0.50) KMT2ARAB9AALDH1A1MAPTMEN1
SCHEMBL2193466 0.82 SYK (0.39) PDE5AKMT2ARAD52MEN1ATM
SCHEMBL2191371 0.81 BRAF (0.33) TSHRNPC1RAB9AHSD17B10ALDH1A1
SCHEMBL2192476 0.81 MAPT (0.44) KMT2ASMN1; SMN2CDK5CDK5R1NPC1
SCHEMBL2196525 0.79 EPHX2 (0.48) KMT2ATSHRSMN1; SMN2NPC1RAB9A
SCHEMBL2194055 0.79 LMNA (0.33) KMT2AKDM4EALDH1A1MEN1
SCHEMBL2194873 0.79 CXCR2 (0.40) KMT2ASMN1; SMN2KDM4EAURKAEGFR
SCHEMBL2193574 0.78 KHK (0.39) KMT2ASMN1; SMN2HSD17B10ALDH1A1MAPT
SCHEMBL2195557 0.77 EPHX2 (0.46) KMT2ATSHRSMN1; SMN2RAB9AKDM4E
SCHEMBL2196576 0.76 HSD17B10 (0.35) KMT2AIGF1RKDM4EAURKAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507473-B2 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders ARENA PHARMACEUTICALS, INC. (US) 2013-08-13 US disclosed
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2011-07-14 US disclosed
WO-2010030360-A1 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS GPR84, GPR119, GPR65 PDE5A 1383/4885KMT2A 3713/4885TSHR 284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.